title: [Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study].
abstract: BACKGROUND
  adalimumab has been shown in placebo-controlled clinical trials and uncontrolled studies to be effective in luminal and perianal fistulizing CD.
  
  
  OBJECTIVE
  to evaluate the efficacy and safety of adalimumab for induction and maintenance therapy in CD.
  
  
  METHODS
  twenty-two patients with CD treated with adalimumab (16 for luminal disease and 6 for active perianal fistulizing disease) were included. Twenty-one patients had previously received IFX. All patients received induction therapy with 160 mg s.c. at week 0, and 80 mg s.c. at week 2. Responders received maintenance therapy with 40 mg s.c. every 14 days. Response was assessed at 4 weeks after the initial dose, and classified as remission, partial response, or non-response.
  
  
  RESULTS
  after induction, 25% of patients with luminal disease had a complete remission, and 56.3% had a partial response. Clinical response was maintained in 71.6% of patients at 1 year, in 53.7% at 18 months, and in 35.8% at 48 months. No differences in response were observed between patients with hypersensitivity reactions or loss of response to IFX.All patients with perianal fistulizing disease (n = 6) had been previously treated with IFX. After induction 16.7% entered remission, and 66.7% had a partial response. All patients maintained remission or response over time, with a median follow-up of 15 months.
  
  
  CONCLUSIONS
  adalimumab is an effective and safe treatment for the induction and maintenance of response in luminal and perianal fistulizing CD. These results confirm that the findings obtained in controlled clinical trials are reproducible in clinical practice.
authors.affiliation: Unidad de Enfermedad Inflamatoria Intestinal. Servicio de Aparato Digestivo. Madrid. Spain.
authors.forename: N
authors.initials: N
authors.lastname: López Palacios
authors.forename: J L
authors.initials: JL
authors.lastname: Mendoza
authors.forename: C
authors.initials: C
authors.lastname: Taxonera
authors.forename: R
authors.initials: R
authors.lastname: Lana
authors.forename: M
authors.initials: M
authors.lastname: Fuentes Ferrer
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Rubio
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D012003:Rectal Fistula / Q000188:drug therapy / Q000209:etiology; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab